MOTIVATION LETTER Aerska raised 32 million euro to deliver AOC therapies across the blood-brain barrier. That capital is a venture round, not a grant. I am not applying for funding. I am writing to register as a potential research collaborator whose computational methods directly address the transport physics that Aerska's platform must solve. My ergofluids project models macromolecular drug-vehicle transport through dense, non-Newtonian tumor tissue using Koopman-operator methods extended with a Mori-Zwanzig memory kernel. The primary pre-registered gate against digitized published data did not pass, and I reported that result directly. The method-development pipeline remains active, and the synthetic-data gates passed. Aerska's brain shuttle technology faces the same class of transport problem: a large molecule must navigate a heterogeneous, viscoelastic medium. My dynamical-systems approach could provide a simulation layer that predicts which shuttle geometries and surface chemistries penetrate fastest. I hold a B.Pharm from the University of Ibadan, am enrolled in the M.Sc. Digital Health at Hasso Plattner Institute starting winter 2026/27, and have published five preprints on computational pharmacology, addiction neuroscience, and topological data analysis for drug-protein interfaces. My CCT model, a tripartite ODE framework for reward-memory encoding, confirmed all five pre-registered hypotheses with posterior super-additivity of 13 to 22 percentage points across model versions. My TOPOLOGIX pipeline uses ESM-2 protein-language-model delta-embeddings and Morgan fingerprints to predict drug-resistance mutations from sequence alone, achieving AUROC 0.804 on the Platinum benchmark while covering 100 percent of mutations versus approximately 18 percent for structure-limited tools. I am Nigerian, 29, and an independent researcher. I have no lab, no institutional overhead, and no conflict of interest with Aerska's commercial timeline. I can deliver a calibrated transport simulation for a specific AOC candidate within six months using open-source tools and published literature parameters. If Aerska's scientific team is interested, I will share the ergofluids codebase, the pre-registration document, and the negative-result report. No NDA required for the initial conversation. RESEARCH STATEMENT My research spans three domains that converge on the problem Aerska's platform must solve: how to move a large molecule through a complex biological medium to a specific neural target. First, the ergofluids project. I extended Dynamic Mode Decomposition with a Mori-Zwanzig memory kernel to model macromolecular transport through dense tumor interstitium. The synthetic-data validation passed. The first real-data gate, tested against digitized published figures, did not meet its primary pre-registered criterion. I reported that result without reframing. The method is a validation pipeline that can be re-targeted to any transport medium, including brain parenchyma. The code is on GitHub under the AmunRaPtah account, and the pre-registration is on OSF. Second, the TOPOLOGIX pipeline. I replaced structure-based resistance prediction with sequence-based methods. Using ESM-2 delta-embeddings and Morgan fingerprints with a Random Forest classifier, I achieved AUROC 0.804 on the Platinum benchmark and 0.634 on SKEMPI 2.0. This covers 100 percent of mutations, whereas structure-limited tools like mCSM-lig cover approximately 18 percent. For Aerska, this means I can predict which mutations in a target receptor will confer resistance to an AOC conjugate before the conjugate is synthesized. Third, the neurocascade simulation engine. I coupled pharmacokinetics to receptor-binding to Wilson-Cowan circuit dynamics to behavioral-readout ODE layers. Three receptor systems are calibrated: mu-opioid, D2 dopamine, and GABA-A. All 62 tests pass. This engine can simulate the downstream circuit effects of an AOC that modulates a specific receptor population, providing a bridge from molecular delivery to behavioral outcome. I am enrolled in the M.Sc. Digital Health at Hasso Plattner Institute starting winter 2026/27. My B.Pharm is from the University of Ibadan. I have endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. I work independently, on my own compute infrastructure, with no institutional overhead. COLLABORATION PROPOSAL Aerska's brain shuttle technology delivers AOC therapies across the blood-brain barrier. The central scientific question is: once across, how does the shuttle-conjugate complex move through brain parenchyma to reach its target cell population? This is a transport problem in a heterogeneous, viscoelastic, charged medium. My ergofluids methods are designed for exactly this class of problem. I propose a six-month collaboration with the following deliverables. One. A calibrated transport simulation for one Aerska AOC candidate, parameterized from published literature on brain extracellular matrix composition, interstitial fluid pressure, and AOC molecular weight and surface charge. The simulation will output predicted penetration depth and time-to-target for three shuttle geometries. Two. A resistance-mutation screen using the TOPOLOGIX pipeline for the target receptor of the AOC candidate. Output will be a ranked list of single-point mutations most likely to reduce binding affinity, with confidence intervals from the Random Forest classifier. Three. A circuit-level simulation using neurocascade to predict the behavioral effect of the AOC at three dose levels, assuming the transport simulation's predicted concentration at the target site. I will work independently, on my own hardware, using open-source tools. I will share all code, data, and pre-registration documents. I will not file patents or claim IP. The collaboration ends after six months unless both parties agree to extend. My fee is 15,000 euro, payable in two tranches: 7,500 at signing and 7,500 at delivery of the three deliverables. I am open to alternative arrangements, including deferred payment or equity in a separate research entity, but I will not accept a work-for-hire contract that assigns my IP to Aerska. CHECKLIST - [ ] Verify that Aerska accepts unsolicited research collaboration proposals from independent researchers. - [ ] Confirm that the contact email on the Aerska website accepts external proposals. - [ ] Prepare a one-page technical summary of the ergofluids method with the pre-registration DOI and GitHub repository link. - [ ] Prepare a one-page summary of the TOPOLOGIX pipeline with the AUROC values and benchmark names. - [ ] Prepare a one-page summary of the neurocascade engine with the 62/62 test-passing statistic. - [ ] Attach CV with ORCID, GitHub, and personal site. - [ ] Attach the ergofluids pre-registration document. - [ ] Attach the TOPOLOGIX preprint. - [ ] Attach the neurocascade preprint. - [ ] Send proposal to Aerska's scientific contact or general inquiries address. - [ ] Follow up after 14 days if no response. EDITOR NOTES - Eligibility risk: Aerska's 32 million euro round is venture capital, not a grant. The applicant is not applying for funding but proposing a paid collaboration. This must be clear in the first paragraph to avoid being filtered as a grant application. - Fact verification needed: Confirm that Aerska's brain shuttle technology is indeed an AOC delivery platform and that the company has a scientific contact or open collaboration policy. The EU-Startups article may not contain this detail. - Gap: The applicant's fee of 15,000 euro is an estimate. The applicant should decide on a specific number and be prepared to negotiate. The profile does not state a preferred rate. - Gap: The applicant's timeline of six months is an estimate. The applicant should verify that the ergofluids pipeline can be re-targeted to brain parenchyma within that period, given that the first real-data gate did not pass. - Gap: The applicant should confirm that the M.Sc. Digital Health enrollment at HPI/Potsdam does not create a conflict of interest or require institutional approval for external collaborations.